timothy sykes logo

Stock News

Soleno Therapeutics Reports Impressive Earnings Amid Market Volatility

Ellis HobbsAvatar
Written by Ellis Hobbs Reviewed by Jack Kellogg Fact-checked by Tim Sykes
Updated 11/9/2025, 11:16 am ET | 6 min
Soleno Therapeutics Reports Impressive Earnings Amid Market Volatility Thumbnail

Soleno Therapeutics Inc.’s stocks have been trading up by 10.24 percent after promising treatment results boosted confidence.

Healthcare industry expert:

Analyst sentiment – positive

  1. Market Position & Fundamentals: Soleno Therapeutics (SLNO) has demonstrated a strong market position with the revenue surge to $66 million in Q3, surpassing both prior expectations and its own lack of reported revenue the previous year. Despite this revenue strength, key profitability ratios indicate significant challenges, with a negative EBIT margin of -76.8% and pre-tax profit margin of -287.7%, reflecting high operating costs relative to revenue despite a gross margin of 98.1%. Financially, the company benefits from strong liquidity with a current ratio of 16.1 and low debt-to-equity of 0.11, positioning it well for strategic investments or acquisitions. However, the negative return on equity of -36.03% highlights a need for improvement in capital utilization.

  2. Technical Analysis & Trading Strategy: Observing SLNO’s recent weekly price movement, there is a clear downward trend from a high of 66.461 to a close at 48. The price action suggests a bearish outlook, reinforced by downward momentum across successive weeks. Trading volume consistency indicates potential further declines unless immediate resistance at $50 is overcome. The narrow range in the last trading days accentuates consolidation, but breaching key support at $42.86 would necessitate caution. A trading strategy might include short positions if prices revisit and fall below $43, with a stop-loss set at $48 to safeguard against sharp inversions. Cautious entry is advised until a clear reversal pattern establishes confidence in upward momentum.

  3. Catalysts & Outlook: Recent news paints an optimistic picture of Soleno Therapeutics with its Q3 results exceeding expectations: an EPS of $0.47 against $0.06 projected, and revenue outpacing estimates at $66 million. Such performance is driven largely by the successful launch of VYKAT XR for PWS, indicating substantial acceptance. Despite a Wells Fargo price target downgrade from $123 to $106, the sustained Overweight rating underlines potential growth driven by Vykat XR. However, the 22% after-hours stock drop post-earnings illustrates market caution and potential profit-taking. Strategic opportunities, including potential M&A activity, could create further value. Key support and resistance levels range between $40 to $50. My overall outlook remains positive, anticipating notable growth potential owing to the drug’s market positioning.

Candlestick Chart

Weekly Update Nov 03 – Nov 07, 2025: On Sunday, November 09, 2025 Soleno Therapeutics Inc. stock [NASDAQ: SLNO] is trending up by 10.24%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

Soleno Therapeutics showcased a financial performance that far exceeded expectations this quarter, illustrating a robust growth trajectory. The company reported a Q3 revenue surge to $66M, impressively higher than the FactSet estimate of $48.1M. The earnings per share jumped to $0.47, eclipsing Wall Street predictions of $0.06. These results portray a company accelerating on the back of VYKAT XR’s success, an FDA-approved therapy addressing unmet needs for patients with Prader-Willi Syndrome.

The shift to profitability was marked, as net income reached $26M, an eye-catching transition from loss positions encountered previously. However, this financial upturn met an unexpected after-market downturn, with share values retracting by over 22%. Despite Wells Fargo’s adjusted outlook, trimming the price target from $123 to $106, the Overweight rating remains indicative of VYKAT XR’s billion-dollar potential. This mixed market response could signal apprehension surrounding broader business strategies or the implications of speculative M&A talks rumored to be in the air.

From a broader perspective, examining the technical data exhibits intriguing prospects for traders. The stock price’s landscape experienced marked volatility with key price adjustments observed. Initial trading presented an optimistic start at $65.65, which then showed erratic closing prices that underscored the quivering market sentiment. A subsequent drop to an even lower $43.54 before finally stabilizing at $48 reveals the turbulence, likely exacerbated by external whispers of potential acquisitions and profitability surprises.

More Breaking News

Conclusion

The current market narrative surrounding Soleno Therapeutics underscores a classic juxtaposition of outstanding financial results against an unsuspected stock price depreciation. With VYKAT XR tangibly driving positive revenue and earnings leaps, market reactions suggest deeper strategic queries. As Soleno leans into an evolving sector role, rumors of mergers and acquisitions loom large, inviting speculation on its future course. Visibility on these strategic dynamics and the potential realization of VYKAT XR as a cornerstone product will guide future market alignment and sentiment.

The forthcoming decisions and disclosures are poised as pivotal points for stakeholders eagerly tracking Soleno’s trajectory. As millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” Amid the symptomatic volatility, Soleno Therapeutics stands at a crossroads of opportunity where calculated strategic maneuvers and market confidence consolidation remain key. In sum, while immediate fluctuations present a paradox, the company’s long-term prospects rest substantially on its capacity to navigate these choppy waters with strategic acumen and operational clarity.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply
Author card Timothy Sykes picture

Ellis Hobbs

Trainer and Mentor on Tim Sykes’ Trading Challenge
He teaches webinars on Tim Sykes’ Trading Challenge He treats trading like a business, not a hobby He emphasizes taking small risks — “If you get the process right, money is a forgone conclusion.”
Read More

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”